protocolSection identificationModule nctId: NCT06294652, orgStudyIdInfo id: AGMT_Lymphoma_Reg, briefTitle: AGMT Austrian Lymphoma Registry, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-27, primaryCompletionDateStruct date: 2033-12-31, completionDateStruct date: 2033-12-31, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Arbeitsgemeinschaft medikamentoese Tumortherapie, class: OTHER, descriptionModule briefSummary: Lymphomas are a group of cancers that originate in the lymphatic system, a key component of the immune system. They can be broadly categorized into two main types: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).There are different subtypes of HL, including classical Hodgkin lymphoma (cHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). The subtypes of cHL include nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted.Non-Hodgkin lymphomas are more diverse and comprise a wide range of subtypes, each with distinct genetic, molecular, and clinical features. Common subtypes of NHL include Diffuse large B-cell lymphoma (DLBCL), Follicular lymphoma (FL), Mantle cell lymphoma (MCL), Chronic lymphocytic leukemia (CLL), myeloma, and other rarer subgroups.Many of these diseases typically present with lymph node enlargement, bone marrow infiltration, general and lymphoma subtype specific symptoms and laboratory abnormalities.Novel agents have improved the prognosis of high-risk lymphoma patients in the front-line and relapsed setting and more accurate prognostic tools enable less intensive treatment for low-risk patients, while maintaining their good prognosis.Lymphoma disease have not been systematically assessed in Austria to date. This medical registry of the AGMT is thus the first Austrian-wide standardized documentation of epidemiology, clinical course and molecular and other biologic data of this disease. As lymphomas are a very heterogeneous group, not all subtypes will always be documented simultaneously in this registry. Which lymphoma subtype is to be documented can change over time, depending on which clinical question is currently in focus., conditionsModule conditions: Lymphoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: OTHER, enrollmentInfo count: 4000, type: ESTIMATED, outcomesModule primaryOutcomes measure: General Characteristics, primaryOutcomes measure: Genetic Profiling, primaryOutcomes measure: Proportion of lymphoma patients in Austria that require treatment, primaryOutcomes measure: Proportion of lymphoma patients in Austria under active surveillance, primaryOutcomes measure: Number of patients with concomitant diseases, primaryOutcomes measure: Number of treatment and outcome of treatment, primaryOutcomes measure: Patient Outcome, primaryOutcomes measure: Toxicities, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Universitätsklinik für Innere Medizin III, PMU Salzburg, status: RECRUITING, city: Salzburg, zip: 5020, country: Austria, contacts name: Richard Greil, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 47.79941, lon: 13.04399, hasResults: False